Please login to the form below

Not currently logged in
Email:
Password:

Cell Therapeutics

This page shows the latest Cell Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn

Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn

The acquisition will help accelerate research into sickle cell disease. Pfizer and Global Blood Therapeutics (GBT) have announced that Pfizer will acquire GBT. ... SCD affects around 4.5 million people worldwide, with over 45 million people living with

Latest news

More from news
Approximately 8 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • Keeping up with the developing regulatory requirements for gene and cell therapies Keeping up with the developing regulatory requirements for gene and cell therapies

    A crucial challenge faced by cell and gene therapy developers is the necessity to balance clinical considerations with logistical ones such as manufacturing. ... must create manufacturing processes for cell and gene therapies that aren’t just rapidly

  • Deal Watch October 2018

    Joint development using SQZ’s cell therapy. platform. $1.375B. Option. Ionis. RNA‐targeted therapeutics for complement mediated. ... Acquisition. $2B. Tango Therapeutics/. Gilead Sciences. Pipeline of up to 5 targeted immuno‐oncology.

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer, benign gynaecological disorders (marketed). ... Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody

  • Deal Watch November 2016 Deal Watch November 2016

    One piece of unwelcome news this month was from Juno Therapeutics, which announced it had halted a phase 2 trial of JCAR015, its CAR T cell immunotherapeutic, in patients with relapsed ... This is despite some positive news for Juno released at the

  • Deal Watch February 2016 Deal Watch February 2016

    licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting NY-ESO-1 (p1/2); 4 other progs and combination studies. ... acquisition - product. 190. Annapurna

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

  • Gamida Cell strengthens leadership team Gamida Cell strengthens leadership team

    Appoints Josh Hamermesh and Paul Nee. Cellular and immune therapeutics group Gamida Cell has appointed a new chief business officer in the form of Josh Hamermesh. ... Alongside Hamermesh, Gamida Cell has appointed Paul Nee (pictured left) as its vice

  • Rubius Therapeutics adds to its board of directors Rubius Therapeutics adds to its board of directors

    Francis Cuss and Catherine Sohn join the US biotech. US biotech Rubius Therapeutics has made two appointments to its board of directors with the addition of Francis Cuss and Catherine Sohn ... Alongside Cuss, Catherine Sohn, currently non-executive

  • Rubius Therapeutics strengthens senior team Rubius Therapeutics strengthens senior team

    Four new hires join the US-based company. Rubius Therapeutics, a company focused on creating Red-Cell Therapeutics, has bolstered its senior team with the addition of four new hires. ... Chris and the rest of the team will play a pivotal role in bringing

  • Bone Therapeutics strengthens clinical development team Bone Therapeutics strengthens clinical development team

    I look forward to working with the Bone Therapeutics team to realise the potential of its ground breaking products for the benefits of the patients.”. ... Thomas Lienard, chief executive officer at Bone Therapeutics, said: “His vast expertise in cell

  • David Epstein joins Flagship Pioneering as executive partner David Epstein joins Flagship Pioneering as executive partner

    In this newly-created position, Epstein will begin working with Rubius Therapeutics, a red blood cell-focused exploratory venture within the Flagship portfolio, as chairman of its board.

More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    Novel technologies, coupled with programmes designed to drive cell and gene research and development, are ushering in a new era of therapies. ... society. “We look at the manufacturing challenges we are facing for emerging healthcare products, such as

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...